New clinical application of high-intensity focused ultrasound: local control of synovial sarcoma

Xiaoye Hu†, Hongke Cai†, Meiqi Zhou1, Haifei He1, Wei Tian1, Yue Hu1, Lirong Chen2 and Yongchuan Deng1*

Abstract

High-intensity focused ultrasound (HIFU) is playing an increasingly important role in cancer therapy. Primary synovial sarcomas of the chest wall are extremely rare. We report the first case of noninvasive HIFU therapy for the control of synovial sarcoma. A 51-year-old man was diagnosed with spindle cell sarcoma on the left chest wall through lumpectomy. After four cycles of chemotherapy, local recurrence of the sarcoma was detected. Subsequent extended resection confirmed synovial sarcoma. After five cycles of a new chemotherapy option, the sarcoma relapsed again. Then the patient received five courses of HIFU; this completely ablated the sarcoma without complications. No chemotherapy, radiotherapy, or biological therapy has been applied since. Now the patient is stable and has a high quality of life.

Keywords: Cancer therapy, High-intensity focused ultrasound, Noninvasive surgery, Synovial sarcoma

Background

Synovial sarcoma is a type of rare sarcoma in the soft tissue near the large joints of the arm or leg. Primary synovial sarcoma of the chest wall is extremely rare. The cytological features of the monophasic spindle cell and biphasic subtypes of synovial sarcoma, samples of which were obtained through fine needle aspiration, have been reported in several case studies [1]. Surgery is the mainstream therapy for synovial sarcoma. However, the post-surgery recurrence rate is still as high as 60% [2]. Moreover, synovial sarcoma is not sensitive to chemotherapy or radiotherapy [3]. So far, no report of high-intensity focused ultrasound (HIFU) therapy for synovial sarcoma has been found in the English literature. This report presents a case of synovial sarcoma of the left chest wall. Two surgical procedures and postoperative chemotherapy failed to control the tumor but HIFU therapy achieved good clinical efficacy.

Case presentation

A solid texture mass, 2 cm in diameter, was found on the left chest wall of a 51-year-old man accompanied with local swelling and tenderness 1 year ago. Lumpectomy was performed in a local hospital. Postoperative pathological analysis confirmed the mass to be a spindle cell sarcoma. The patient was treated with a chemotherapy regimen of MTX 14.5 d1 + MTX 14.5 d8 + DDP 180 mg d15 + ADM 110 mg d17. After four cycles of chemotherapy, a similar mass with a more solid texture and some tenderness was found in the surgical site. Therefore, the patient was admitted to our hospital for a second surgery, expanded resection. Postoperative immunohistochemistry results indicated ER−, AR−, CK(Pan)+, CD34−, EMA−, CerbB2−, S-100+, Vimentin++, EGFR−, P63−, SMA+, Calponin−, D2-40+, MBP−, CD99++, β-catenin++, confirming diagnosis of synovial sarcoma. The patient received a new chemotherapy regimen of IFO 2 d1-5 + VP16 0.1 d1-5. However, follow-up magnetic resonance imaging (MRI) revealed that the tumor relapsed again after five cycles of chemotherapy. A new therapy plan was designed: HIFU. The HIFU procedure was performed using an FEP-BYO2 HIFU system (Yuande Biomedical Engineering Co. Ltd, Beijing, China). A vertical scanning mode was chosen with a slice thickness of 2 mm. The ultrasonic transmitter worked at a frequency of 1.1 MHz and 11.0 MHz. GE LOGIQ 400CL was used for real-time monitoring during the therapy. The ultrasonic power was 130 W. Detailed therapeutic parameters were as follows: T1/T2 990 ms/10 ms; 40 transmissions per therapeutic point with a distance of 2 mm between adjacent therapeutic points;
treatment of each unit (five therapeutic points) for 200 seconds with an interval of 2 minutes between each unit; a spacing of 5 mm between adjacent treatment slices. The ablation effect was measured by MRI after the HIFU procedure.

After the first HIFU procedure, MRI demonstrated that the treated region was indicative of coagulation necrosis and homogeneous enhancement at the edge of the tumor. In total, five HIFU procedures were conducted, on 15 February 2011, 26 April 2011, 30 May 2011, 28 June 2011, and 6 September 2011. MRI conducted on 11 January 2011 and 7 September 2011 found complete coagulation necrosis in the therapeutic area (Figure 1A and B). Biopsy results before and after HIFU therapy are shown in Figure 2. Residual tumor cells were not found in repeated biopsy tests. HIFU completely ablated the tumor without complications and no further chemotherapy, radiotherapy or biological therapy was required for tumor control. The patient is now stable with a high quality of life. Further collection and analysis of follow-up data is underway.

Discussion
Synovial sarcoma is characterized by local recurrence and difficulty in treatment. Surgery is the mainstream option for synovial sarcoma, accompanied by chemotherapy and radiotherapy. Further studies on molecular biology have revealed specific oncogene mutations and corresponding protection expression could serve as therapeutic targets [4]. Unfortunately, researchers have proved that chemotherapy and radiotherapy not only failed to improve progression-free survival or overall survival rate, but also led to poor life quality, owing to severe side effects [5]. With focused beams, HIFU can reach deep tissue and deliver localized warming, with temperatures reaching 70°C within 0.5 to 5 seconds [6]. HIFU could achieve coagulation necrosis through thermal effects, cavitation and mechanical effects without affecting normal tissues outside the therapeutic area [7]. HIFU has been widely used for prostate cancer [8], pancreatic cancer [9] and uterine fibroids [10]. Further in-depth research has focused on integration of HIFU therapy and chemotherapy or biological therapy.
radiotherapy [11]. Currently, HIFU is being applied to treat a wider range of diseases: for example, Thomas Charrel [12] applied HIFU for the treatment of glaucoma. However, the application of HIFU is still at an exploratory stage. Many issues remain unsolved, such as the exact molecular biological effect of HIFU treatment, and how to improve therapeutic and dose efficiency. Nevertheless, HIFU represents an effective, repeatable and minimally invasive therapy option.

Conclusions
This is the first report of effective noninvasive therapy for local control of synovial sarcoma. Without doubt, the development of HIFU will bring revolutionary technologies for cancer therapy.

Consent
Written informed consent was obtained from the patient’s relatives for publication of this case report and accompanying images. A copy is available for review from the editor-in-chief of this journal.

Abbreviations
H&E: Hematoxylin and eosin; HIFU: High-intensity focused ultrasound; MRI: Magnetic resonance imaging.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
XH and HC collected the data and drafted the manuscript. MZ performed data analysis. HH, YH, and WT recruited the patient and collected study materials. YD designed the study and revised the manuscript. All authors read and approved the final manuscript.

Acknowledgements
We express our gratitude to the Cancer Institute, Key Laboratory of Cancer Prevention and Intervention, China.

Author details
1Department of Surgical Oncology, Second Affiliated Hospital, Zhejiang University College of Medicine, No. 88 Jiefang Road, Hangzhou, PR China.
2Department of Pathology, Second Affiliated Hospital, Zhejiang University College of Medicine, No. 88 Jiefang Road, Hangzhou, PR China.

Received: 29 August 2012 Accepted: 22 September 2013
Published: 8 October 2013

References
1. Akerman M, Domanski HA: The complex cytological features of synovial sarcoma in fine needle aspirates, an analysis of four illustrative cases. Cytopathology 2007, 18:234–240.
2. Lewis JJ, Antonescu CR, Leung DH, Blumberg D, Healey JH, Woodruff JM, Brennan MF: Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J Clin Oncol 2000, 18:2087–2094.
3. Spillane AJ, AHemm R, Judson IR, Fisher C, Thomas JM: Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment. J Clin Oncol 2000, 18:3794–3803.
4. Verweij J, Baker LH: Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular aberrations. Eur J Cancer 2010, 46:836–838.
5. Siegel HJ, Sessions W, Casillas MA Jr, Said-AHNaief N, Lander PH, Lopez-Ben R: Synovial sarcoma: clinicopathologic features, treatment, and prognosis. Orthopedics 2007, 30:1020–1025.
6. Shaw A, Hodnett M: Calibration and measurement issues for therapeutic ultrasound. Ultrasoni 2008, 48:234–252.
7. Tempary CM, McDannold NJ, Hyynen K, Jolesz FA: Focused ultrasound surgery in oncology: overview and principles. Radiology 2011, 259:39–56.
8. Rouviere O, Gas L, Grouin N, Melé-Lechevallier F, Gelet A, Dantony E, Rabilloud M, Chapelon JY, Lyonnert D: Prostate cancer ablation with transrectal high-intensity focused ultrasound: assessment of tissue destruction with contrast-enhanced US. Radiology 2011, 259:583–591.
9. Wang K, Chen Z, Meng Z, Lin J, Zhou Z, Wang P, Chen L, Liu L: Analgesic effect of high intensity focused ultrasound therapy for unresectable pancreatic cancer. Int J Hyperthermia 2011, 27:101–107.
10. Meng X, He G, Zhang J, Han Z, Yu M, Zhang M, Tang Y, Fang L, Zhou X: A comparative study of fibroid ablation rates using radio frequency or high-intensity focused ultrasound. Cardiovasc Interv Radiol 2010, 33:794–799.
11. Lee JY, Choi BI, Ryu JK, Kim YT, Hwang JH, Kim SH, Han JK: Concurrent chemotherapy and pulsed high-intensity focused ultrasound therapy for the treatment of unresectable pancreatic cancer: initial experiences. Korean J Radiol 2011, 12:76–186.
12. Charrel T, Apetel F, Birer A, Chavrier F, Romano F, Chapelon JY, Denis P, Lafon C: Development of a miniaturized HIFU device for glaucoma treatment with conformal coagulation of the ciliary bodies. Ultrasound Med Biol 2011, 37:742–754.

Cite this article as: Hu et al.: New clinical application of high-intensity focused ultrasound: local control of synovial sarcoma. World Journal of Surgical Oncology 2013 11:265.

Submit your next manuscript to BioMed Central and take full advantage of:

• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit